Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

SIMPLE SUMMARY: Treatment results of acute myeloid leukemia (AML) in elderly patients are unsatisfactory. We investigated in an open label randomized phase II study whether addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy would improve outcome in this population. 231 AM...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Janssen, Jeroen, Löwenberg, Bob, Manz, Markus, Bargetzi, Mario, Biemond, Bart, Borne, Peter von dem, Breems, Dimitri, Brouwer, Rolf, Chalandon, Yves, Deeren, Dries, Efthymiou, Anna, Gjertsen, Bjørn-Tore, Graux, Carlos, Gregor, Michael, Heim, Dominik, Hess, Urs, Hoogendoorn, Mels, Jaspers, Aurelie, Jie, Asiong, Jongen-Lavrencic, Mojca, Klein, Saskia, van der Klift, Marjolein, Kuball, Jürgen, van Lammeren-Venema, Danielle, Legdeur, Marie-Cecile, van de Loosdrecht, Arjan, Maertens, Johan, Kooy, Marinus van Marwijk, Moors, Ine, Nijziel, Marten, van Obbergh, Florence, Oosterveld, Margriet, Pabst, Thomas, van der Poel, Marjolein, Sinnige, Harm, Spertini, Olivier, Terpstra, Wim, Tick, Lidwine, van der Velden, Walter, Vekemans, Marie-Christiane, Vellenga, Edo, de Weerdt, Okke, Westerweel, Peter, Stüssi, Georg, van Norden, Yvette, Ossenkoppele, Gert
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7914531/
https://ncbi.nlm.nih.gov/pubmed/33562393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040672
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados